StockData

Altimmune vs Kazia Therapeutics

ALT and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALT and KZIA compare

Altimmune scores higher on the StockData Score (4 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALTKZIA
Size and price
Market cap$298M–
Share price$1.53$5.31
Change, 1 year−63.3%−15.3%
Change, 5 years−85.3%−98.9%
Beta (5Y)1.904.08
Employees1314
StockData Score
Total score4 (better)1
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score2 (better)1
Dividend score00
Valuation
P/B0.6×–
FCF yield−25.7%–
Growth
Revenue growth (TTM)–−98.2%
Revenue growth, 5Y average−65.3%–
Profitability
Net margin–−49291%
Return on equity−28.9%–
Return on invested capital−90.4%–
Financial health
Debt / equity0.07–
Interest coverage−28.3×–
Current ratio26.78 (better)2.87
Altman Z-score1.63–
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−37.0%–
Shareholder yield−37.0%–
Ownership
Held by institutions77.9%0.45%
Held by insiders0.56%0.29%
Insider net buying, 12 months$452K–
Superinvestors holding11
Short interest, % of float21.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.